Request Download Report

View Synopsis & Table of Content
{reportSlug=global-ovarian-cancer-drugs-market, reportId=20244, mktKeyword=Ovarian Cancer Drugs, cagr=8.30, publishDate=Apr 2024, priceOption2=7500, reportTitle=Ovarian Cancer Drugs Comprehensive Study by Type (PARP inhibitors, PD-L1 inhibitors, Angiogenesis Inhibitors, Others), Application (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Others), Treatment Categories (Chemotherapy, Radiation therapy, Immunotherapy, Autologous stem-cell transplantation, Targeted Therapy), Disease Type (Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, Primary Peritoneal Carcinoma), Chemotherapy Drugs (Carboplatin, Cisplatin, Docetaxel, Paclitaxel, Other Medication (Cyclophosphamide, Doxorubicin, Gemcitabine, Oxaliplatin, and Topotecan).), Physical Examination (Biopsy, Blood tests, Human Chorionic Gonadotropin (hCG) test, Ultrasound, MRI (Magnetic resonance imaging), PET (Positron emission tomography), CT scans, Biopsy, Blood tests, Human Chorionic Gonadotropin (hCG) test, Ultrasound, MRI (Magnetic resonance imaging), PET (Positron emission tomography), CT scans), Pricing analysis (IPP, OPP, RAP), Distribution channel (Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy) Players and Region - Global Market Outlook to 2030, baseYr=2023, totalTableFig=220, priceOption1=3750, forecastYr=2030, noOfPages=211, reportKey=20174, breadcrum=Global Ovarian Cancer Drugs Market}
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Select User Access Type

Key Highlights of Report


Apr 2024 211 Pages 86 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Connect with Us
AMA Research Sales Support

Praveen Kumar

Head - Sales
AMA Research - Asia Pacific Client Engagement Partner

Filza Sayed

APAC Client Engagement Partner